Reflex Decay Test Can Reveal Ear Involvement in Fabry Disease.
Journal
Ear and hearing
ISSN: 1538-4667
Titre abrégé: Ear Hear
Pays: United States
ID NLM: 8005585
Informations de publication
Date de publication:
Historique:
pubmed:
25
3
2021
medline:
21
10
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
Fabry disease (FD) is an X-linked lysosomal storage disorder that causes multisystem involvement, including ear disease. In this study, we aimed to investigate the nature of auditory issues in FD using a wide spectrum of audiological tests. This cross-sectional study was conducted between June 2017 and December 2018. We collected the clinical and laboratory data of 40 eligible FD patients, 45 healthy subjects, and 26 diabetic controls. All patients and controls completed audiologic evaluations that included tympanometry, acoustic reflex threshold test, reflex decay test, pure-tone audiometry, speech audiometry, transient otoacoustic emissions (TEOAEs), high-frequency audiometry, and distortion product otoacoustic emission (DPOAE). In our study population, hearing was reduced at higher frequencies starting at 4 kHz in both the FD and diabetic groups. Regarding the acoustic reflex threshold test, FD and diabetic patients had similar results. In all frequencies, positive decay was significantly more frequent in FD patients when compared with the diabetic patients and healthy controls (p < 0.001 for each ear). The FD patients and healthy controls had similar results for DPOAE testing. We showed that FD patients had a higher rate of reflex decay, indicating retrocochlear involvement. Thus, further investigation of factors associated with retrocochlear involvement could be investigated, such as ABR and speech in noise tests.
Identifiants
pubmed: 33758156
doi: 10.1097/AUD.0000000000001030
pii: 00003446-900000000-98529
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1351-1357Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Antonelli A. R., Bellotto R., Grandori F. Audiologic diagnosis of central versus eighth nerve and cochlear auditory impairment. Audiology, (1987). 26, 209–226.
Brady R. O., Gal A. E., Bradley R. M., Martensson E., Warshaw A. L., Laster L. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med, (1967). 276, 1163–1167.
Desnick R. J., Wasserstein M. P., Banikazemi M. Fabry disease (alpha-galactosidase A deficiency): Renal involvement and enzyme replacement therapy. Contrib Nephrol, (2001a). 136174–192.
Desnick R. J., Ioannou Y. A., Eng C. M. (Schriver C., Beaudet A. L., Sly W. S. (Eds.), α-galactosidase A deficiency: Fabry disease. In The Metabolic and Molecular Basis of Inherited Disease2001b). McGraw-Hill.3733–3774).
Eyermann C., Raguin T., Rohmer D., Noel E., Charpiot A. Cochleovestibular manifestations in Fabry disease: importance of screening and systematic ENT evaluation. Eur Ann Otorhinolaryngol Head Neck Dis, (2019). 136, 273–279.
Germain D. P., Avan P., Chassaing A., Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet, (2002). 3, 10.
Hegemann S., Hajioff D., Conti G., Beck M., Sunder-Plassmann G., Widmer U., Mehta A., Keilmann A. Hearing loss in Fabry disease: data from the Fabry outcome survey. Eur J Clin Invest, (2006). 36, 654–662.
Hunter L. L., Shanaz N. Acoustic Immittance Measures Basic and Advanced Practice. (2014). Plural Publishing, Inc.
Hwu W. L., Chien Y. H., Lee N. C., Chiang S. C., Dobrovolny R., Huang A. C., Yeh H. Y., Chao M. C., Lin S. J., Kitagawa T., Desnick R. J., Hsu L. W. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat, (2009). 30, 1397–1405.
Juchniewicz P., Kloska A., Tylki-Szymańska A., Jakóbkiewicz-Banecka J., Węgrzyn G., Moskot M., Gabig-Cimińska M., Piotrowska E. Female Fabry disease patients and X-chromosome inactivation. Gene, (2018). 641, 259–264.
Kaminsky P., Noel E., Jaussaud R., Leguy-Seguin V., Hachulla E., Zenone T., Lavigne C., Marie I., Maillot F., Masseau A., Serratrice C., Lidove O. Multidimensional analysis of clinical symptoms in patients with Fabry’s disease. Int J Clin Pract, (2013). 67, 120–127.
Katz J. Handbook of Clinical Audiology. (2002). Lippincott, Williams & Wilkins.
Levey A. S., Stevens L. A., Schmid C. H., Zhang Y. L., Castro A. F. 3rd, Feldman H. I., Kusek J. W., Eggers P., Van Lente F., Greene T., Coresh JCKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med, (2009). 150, 604–612.
Mazzoli M., Van Camp G.U.Y., Newton V., Giarbini N., Declau F., Parving A. Recommendations for the description of genetic and audiological data for families with nonsyndromic hereditary hearing impairment. Audiol Med, (2003). 1, 148–150.
Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest, (2004). 34, 236–242.
Meikle P. J., Hopwood J. J., Clague A. E., Carey W. F. Prevalence of lysosomal storage disorders. JAMA, (1999). 281, 249–254.
Mitchell P., Gopinath B., McMahon C. M., Rochtchina E., Wang J. J., Boyages S. C., Leeder S. R. Relationship of Type 2 diabetes to the prevalence, incidence and progression of age-related hearing loss. Diabet Med, (2009). 26, 483–488.
Narożny W., Gromnicki M., Majkowicz M., Kuczkowski J., Sochaczewska A. [Quality of life patients with sudden sensorineural hearing loss]. Otolaryngol Pol, (2014). 68, 69–76.
Rawool V. (Rawool V. W. (Ed.), Auditory neuropathy spectrum disorder including auditory synaptopathy. In Auditory Processing Deficits: Assessment and Intervention. (pp. (2016). Thieme.409–428).
Rodrigues J., Azevedo O., Sousa N., Cunha D., Mexedo A., Fonseca R. Inner ear involvement in Fabry disease: clinical and audiometric evaluation of a large cohort of patients followed in a reference centre. Eur J Med Genet, (2018). 61, 341–347.
Roeser R. J., Valente M., Hosford-Dunn H. Audiology: Diagnosis. (2000). Thieme.
Sakurai Y., Kojima H., Shiwa M., Ohashi T., Eto Y., Moriyama H. The hearing status in 12 female and 15 male Japanese Fabry patients. Auris Nasus Larynx, (2009). 36, 627–632.
Sataloff J., Sataloff R. T. Hearing Loss. (2005). CRC Press.
Schachern P. A., Shea D. A., Paparella M. M., Yoon T. H. Otologic histopathology of Fabry’s disease. Ann Otol Rhinol Laryngol, (1989). 98(5 Pt 1), 359–363.
Sliwinska-Kowalska M. (Lotti M., Bleecker M. L. (Eds.), Chapter 19 - hearing. In Handbook of Clinical Neurology (pp. (2015). Elsevier.341–363).
Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., Desnick R. J. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet, (2006). 79, 31–40.
Suntjens E. B., Smid B. E., Biegstraaten M., Dreschler W. A., Hollak C. E., Linthorst G. E. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy. J Inherit Metab Dis, (2015). 38, 351–358.